• 華中科技大學同濟醫(yī)學院附屬協(xié)和醫(yī)院胰腺外科中心（武漢430022）;

目的 檢測胰腺正常組織、癌組織及癌旁組織中糖酵解關鍵酶〖ＣＤ２乳酸脫氫酶（lacate dehydrogenase, LDH）活性及其同工酶譜變化，分析糖酵解與胰腺癌生物學行為的關系。
方法 收集我院自2006年10月至2008年7月期間收治的12例胰腺導管腺癌患者手術切除標本和12例胰島素瘤等良性病變的正常胰腺組織。LDH活性檢測采用LDH檢測試劑盒； LDH同工酶譜檢測采用法國Sebia hydrasys全自動分析儀。
結(jié)果 與正常胰腺組織相比，癌組織及癌旁組織中LDH活性明顯升高，差異有統(tǒng)計學意義（P＜0.05）； 癌組織及癌旁組織中LDH同工酶譜分析顯示LDH4、LDH5明顯升高，與正常組織相比，差異有統(tǒng)計學意義（P＜0.05）。
結(jié)論 LDH活性及其同工酶譜的變化可能和胰腺癌的發(fā)病機理有關，特異性抑制LDH可能成為新的治療策略。

引用本文： 張樹華,熊炯炘,楊智勇,王春友. 胰腺正常組織、癌組織及癌旁組織LDH活性及其同工酶譜分析. 中國普外基礎與臨床雜志, 2009, 16(2): 129-132. doi: 復制

1. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond [Ｊ]. Cell, 2008; 134(5)：703.
2. Deberardinis RJ. Is cancer a disease of abnormal cellular metabolism? New angles on an old idea [Ｊ]. Genet Med, 2008; 10(11)：767.
3. Deberardinis RJ, Sayed N, Ditsworth D, et al. Brick and brick: metabolism and tumor cell growth [Ｊ]. Curr Opin Genet Dev, 2008; 18(1)：54.
4. 韓明勇， 王家林， 郭其森， 等.血清乳酸脫氫酶水平對肺癌診斷意義的研究[Ｊ].腫瘤防治雜志， 2003； 10(4)：364.
5. Ugurel S. Serum markers for melanoma [Ｊ]. Hautarzt, 2005; 56(2)：173.
6. Boran N, Kayikioˇglu F, Yalva S, et al. Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer [Ｊ]. Gynecol Obstet Invest, 2000; 49(4)：272.
7. Suh SY, Ahn HY. Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: a preliminary study[Ｊ]. Eur J Cancer, 2007; 43(6)：1051.
8. Naruse K, Yamada Y, Aoki S, et al. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis [Ｊ]. Hinyokika Kiyo, 2007; 53(5)：287.
9. Turen S, Ozyar E, Altundag K, et al. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy [Ｊ].Cancer Invest, 2007; 25(5)：315.
10. Shaw RJ. Glucose metabolism and cancer [Ｊ]. Curr Opin Cell Biol, 2006; 18(6)：598.
11. Kondoh H. Cellular life span and the Warburg effect [Ｊ]. Exp Cell Res, 2008; 314(9)：1923.
12. Alcazar O, Tiedge M, Lenzen S. Importance of lactate dehydrogenase for the regulation of glycolytic flux and insulin secretion in insulin-producing cells[Ｊ]. Biochem J, 2000; 352(Pt2)：373.
13. 趙玉沛， 戴夢華.胰腺癌生物治療現(xiàn)狀與進展[Ｊ]. 中國普外基礎與臨床雜志， 2002； 9(6)：371.
14. 趙玉沛.胰腺癌診治現(xiàn)狀與展望[Ｊ].中國普外基礎與臨床雜志， 2003； 10(3)：205.
15. Kroemer G. Mitochondria in cancer[Ｊ]. Oncogene, 2006; 25(34)：4630.
16. Bartrons R, Caro J. Hypoxia, glucose metabolism and the Warburg’s effect[Ｊ]. J Bioenerg Biomembr, 2007; 39(3)：223.
17. Pedersen PL. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen [Ｊ]. J Bioenerg Biomembr, 2007; 39(3)：211.
18. Chen Z, Lu W, Garcia-Prieto C, et al. The Warburg effect and its cancer therapeutic implications [Ｊ]. J Bioenerg Biomembr, 2007; 39(3)：267.
19. Garber K. Energy deregulation: licensing tumors to grow [Ｊ]. Science, 2006; 312(5777)：1158.
20. Pelicano H, Martin DS, Xu RH, et al. Glycolysis inhibition for anticancer treatment [Ｊ]. Oncogene, 2006; 25(34)：4633.
21. 鄒滿意， 陸偉. 糖酵解酶抑制劑抗腫瘤作用的研究進展[Ｊ].武警醫(yī)學院學報， 2006； 15(3)：286.
  1. 1. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond [Ｊ]. Cell, 2008; 134(5)：703.
  2. 2. Deberardinis RJ. Is cancer a disease of abnormal cellular metabolism? New angles on an old idea [Ｊ]. Genet Med, 2008; 10(11)：767.
  3. 3. Deberardinis RJ, Sayed N, Ditsworth D, et al. Brick and brick: metabolism and tumor cell growth [Ｊ]. Curr Opin Genet Dev, 2008; 18(1)：54.
  4. 4. 韓明勇， 王家林， 郭其森， 等.血清乳酸脫氫酶水平對肺癌診斷意義的研究[Ｊ].腫瘤防治雜志， 2003； 10(4)：364.
  5. 5. Ugurel S. Serum markers for melanoma [Ｊ]. Hautarzt, 2005; 56(2)：173.
  6. 6. Boran N, Kayikioˇglu F, Yalva S, et al. Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer [Ｊ]. Gynecol Obstet Invest, 2000; 49(4)：272.
  7. 7. Suh SY, Ahn HY. Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: a preliminary study[Ｊ]. Eur J Cancer, 2007; 43(6)：1051.
  8. 8. Naruse K, Yamada Y, Aoki S, et al. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis [Ｊ]. Hinyokika Kiyo, 2007; 53(5)：287.
  9. 9. Turen S, Ozyar E, Altundag K, et al. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy [Ｊ].Cancer Invest, 2007; 25(5)：315.
  10. 10. Shaw RJ. Glucose metabolism and cancer [Ｊ]. Curr Opin Cell Biol, 2006; 18(6)：598.
  11. 11. Kondoh H. Cellular life span and the Warburg effect [Ｊ]. Exp Cell Res, 2008; 314(9)：1923.
  12. 12. Alcazar O, Tiedge M, Lenzen S. Importance of lactate dehydrogenase for the regulation of glycolytic flux and insulin secretion in insulin-producing cells[Ｊ]. Biochem J, 2000; 352(Pt2)：373.
  13. 13. 趙玉沛， 戴夢華.胰腺癌生物治療現(xiàn)狀與進展[Ｊ]. 中國普外基礎與臨床雜志， 2002； 9(6)：371.
  14. 14. 趙玉沛.胰腺癌診治現(xiàn)狀與展望[Ｊ].中國普外基礎與臨床雜志， 2003； 10(3)：205.
  15. 15. Kroemer G. Mitochondria in cancer[Ｊ]. Oncogene, 2006; 25(34)：4630.
  16. 16. Bartrons R, Caro J. Hypoxia, glucose metabolism and the Warburg’s effect[Ｊ]. J Bioenerg Biomembr, 2007; 39(3)：223.
  17. 17. Pedersen PL. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen [Ｊ]. J Bioenerg Biomembr, 2007; 39(3)：211.
  18. 18. Chen Z, Lu W, Garcia-Prieto C, et al. The Warburg effect and its cancer therapeutic implications [Ｊ]. J Bioenerg Biomembr, 2007; 39(3)：267.
  19. 19. Garber K. Energy deregulation: licensing tumors to grow [Ｊ]. Science, 2006; 312(5777)：1158.
  20. 20. Pelicano H, Martin DS, Xu RH, et al. Glycolysis inhibition for anticancer treatment [Ｊ]. Oncogene, 2006; 25(34)：4633.
  21. 21. 鄒滿意， 陸偉. 糖酵解酶抑制劑抗腫瘤作用的研究進展[Ｊ].武警醫(yī)學院學報， 2006； 15(3)：286.